Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

Proceedings of the National Academy of Sciences of the United States of America
Ruth Arnon, Rina Aharoni

Abstract

Glatiramer acetate (GA, Copaxone, Copolymer 1) is an approved drug for the treatment of multiple sclerosis and is highly effective in the suppression of experimental autoimmune encephalomyelitis in various species. The mode of action of GA is by initial strong promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression. Furthermore, the GA-specific cells in the brain express the antiinflammatory cytokines IL-10 and transforming growth factor beta, in addition to brain-derived neurotrophic factor, whereas they do not express IFN-gamma. Based on this immunomodulatory mode of action, we explored the potential of GA for two other applications: prevention of graft rejection and amelioration of inflammatory bowel diseases. GA was effective in amelioration of graft rejection in two systems by prolongation of skin graft survival and inhibition of functional deterioration of thyroid grafts, across minor and major histocompatibility barriers. In all transplantation systems GA treatment inhibited t...Continue Reading

References

Aug 1, 1971·European Journal of Immunology·D TeitelbaumM Sela
Oct 27, 1995·Science·H Thoenen
Oct 1, 1994·Current Opinion in Immunology·P NickersonT B Strom
May 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M Sykes
Oct 1, 1996·Current Opinion in Immunology·H Auchincloss, H Sultan
Jan 30, 1997·Nature·Y A Barde
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·R AharoniR Arnon
Jan 13, 2000·Scandinavian Journal of Immunology·S J Van Deventer
Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·O NeuhausR Hohlfeld
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·R AharoniR Arnon
Sep 7, 2001·Transplantation·R AharoniM Sela
May 23, 2002·Gastroenterology·William J Sandborn, Stephan R Targan
Apr 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Pedro L VieiraMartien L Kapsenberg
May 29, 2003·Current Drug Targets. Cardiovascular & Haematological Disorders·Anlun Ma, Huifang Chen
Jun 7, 2003·Journal of Autoimmunity·Estelle BettelliVijay K Kuchroo
Jul 2, 2003·Molecular Immunology·Marwan A Masri
Nov 14, 2003·Proceedings of the National Academy of Sciences of the United States of America·Rina AharoniRuth Arnon

❮ Previous
Next ❯

Citations

Jun 4, 2011·Journal of Neurology·Dorothea Buck, Bernhard Hemmer
Sep 1, 2011·Cell and Tissue Research·Filippo CaraciAgata Copani
Mar 5, 2009·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Roberto BergamaschiVittorio Cosi
Nov 4, 2010·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Refik PulMartin Stangel
May 10, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Jun-Jun CaoYan-Qin Shen
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Martin S WeberScott S Zamvil
Aug 7, 2007·Nature Medicine·Martin S WeberScott S Zamvil
Mar 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Danielle BurgerPatrice H Lalive
Sep 30, 2010·Proceedings of the National Academy of Sciences of the United States of America·Rakel CarpinteroDanielle Burger
Apr 13, 2006·Rejuvenation Research·Michael Sela
Jun 27, 2012·Brain : a Journal of Neurology·Gurman KaurLars Fugger
Sep 6, 2007·International Journal of Clinical Practice·B A Cohen, P Rieckmann
Aug 1, 2012·International Journal of Nanomedicine·Jagat R KanwarRupinder K Kanwar
Feb 2, 2013·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Antonietta GentileDiego Centonze
Apr 20, 2010·Expert Opinion on Drug Metabolism & Toxicology·Kenneth P Johnson
Dec 3, 2014·Journal of Neuroinflammation·Hugo González, Rodrigo Pacheco
Sep 18, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Rosario BillettaSalvatore Albani
Dec 17, 2015·Journal of the Neurological Sciences·James AndersonRichard Sachleben
May 29, 2015·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Hugo GonzálezRodrigo Pacheco
Jul 6, 2011·European Journal of Immunology·David J HussAmy E Lovett-Racke
Nov 21, 2009·CNS Neuroscience & Therapeutics·Filippo CaraciAgata Copani
Jan 22, 2014·Journal of Internal Medicine·A H Cross, R T Naismith
Jun 7, 2015·Brain : a Journal of Neurology·Yosef KoronyoMaya Koronyo-Hamaoui

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.